financetom
Business
financetom
/
Business
/
US Steel Faces Q1 Pressures, But Eyes Long-Term Gains From BR2 & Nippon Partnership
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US Steel Faces Q1 Pressures, But Eyes Long-Term Gains From BR2 & Nippon Partnership
Mar 21, 2025 4:00 AM

United States Steel Corporation ( X ) shares are trading lower premarket on Friday. On Thursday, the company guided for the first quarter of 2025 adjusted EPS loss of 53 cents – 49 cents vs. consensus loss of 30 cents.

Also, the company expects adjusted EBITDA of about $125 million in the first quarter of 2025, in line with prior first quarter outlook of $100 million – $150 million.

The company projects the Flat-Rolled segment’s adjusted EBITDA to be lower sequentially on typical seasonal logistics constraints in the mining sector, which is expected to unwind in the second quarter.

United States Steel ( X ) expects higher average selling prices and higher volumes to partially offset this mining impact.

Meanwhile, the company anticipates Mini Mill segment’s adjusted EBITDA to be higher Q/Q on higher shipments.

Apart from this, the European segment’s adjusted EBITDA is expected to improve Q/Q due to an increase in shipments, volume efficiencies, and favorable raw material pricing despite the challenging demand environment in Europe.

On the other hand, the company sees Tubular segment’s adjusted EBITDA to be higher Q/Q led by an increase in prime shipments and rise in average selling prices.

President and Chief Executive Officer David B. Burritt said, ”BR2 is expected to make a significant contribution to our 2025 EBITDA, with run-rate throughput expected during the second half of 2025 and full run-rate capability in 2026.”

“We applaud President Trump’s leadership and advocacy for the American steel industry in his recent tariff announcements. We continue to assess the benefit we expect from these tariff policies.”

”Combined with the partnership with Nippon Steel, which includes investment commitments, technology transfer and innovation, U. S. Steel’s future is extremely bright.”

Investors can gain exposure to the stock via VanEck Steel ETF ( SLX ) and SPDR S&P Metals & Mining ETF .

Price Action: X shares are down 1.34% at $40.51 premarket at the last check Friday.

Read Next:

Billionaire Stanley Druckenmiller Boosts US Steel Stake By 143%: Is He Betting On Merger?

Image via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Interpublic Group Rolls Out New Service for Healthcare Marketers
Interpublic Group Rolls Out New Service for Healthcare Marketers
Aug 29, 2024
12:07 PM EDT, 08/29/2024 (MT Newswires) -- Interpublic Group (IPG) said Thursday it has launched a new offering for healthcare marketers that includes data-driven media expertise to health and wellness brands. The Mediabrands Health offering will be a part of IPG Mediabrands, the company's media and marketing solutions division. Melissa Gordon-Ring will lead Mediabrands Health, while former Initiative Head of...
Why Is Polestar Automotive Stock Diving Today?
Why Is Polestar Automotive Stock Diving Today?
Aug 29, 2024
Polestar Automotive Holding UK PLC ( PSNY ) shares are trading lower on Wednesday. The Swedish electric performance car brand disclosed that Michael Lohscheller will become CEO effective October 1, 2024. Lohscheller will succeed Thomas Ingenlath, who is stepping down after successfully positioning the brand for its next phase. Michael Lohscheller has formerly worked as the CEO of Opel, VinFast, and...
Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease
Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease
Aug 29, 2024
Thursday, Gain Therapeutics, Inc. ( GANX ) released results from the Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of GT-02287. The company previously announced that no discontinuations or serious adverse events were reported when the study concluded. Also Read: EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson’s Disease. The...
Dick's Sporting Goods Likely to Beat Q2 Estimates, Raise Guidance, Wedbush Says
Dick's Sporting Goods Likely to Beat Q2 Estimates, Raise Guidance, Wedbush Says
Aug 29, 2024
11:10 AM EDT, 08/28/2024 (MT Newswires) -- Dick's Sporting Goods' (DKS) fiscal Q2 earnings are expected to top analyst estimates, but a material deceleration in trends in H2 is likely to limit a potential upside for its shares, Wedbush said in a note Wednesday. Growth is being led by the company's mid-upper income customer demographic skew, differentiated and better access...
Copyright 2023-2026 - www.financetom.com All Rights Reserved